|
|
|||
|
| |||
|
| |||
|
| |||
|
|
|||
|
Ioannis A Voutsadakis, Stergios Doumas, Konstantinos Tsapakidis, Maria Papagianni, Christos N Papandreou, Division of Medical Oncology, University Hospital of Larissa, Larissa 41110, Greece Author contributions: Voutsadakis IA conceptualized and wrote the paper, provided clinical care and performed the research; Doumas S performed research and co-authored the paper; Tsapakidis K and Papagianni M performed research and collected data; Papandreou CN revised the paper. Correspondence to: Ioannis A Voutsadakis, Division of Medical Oncology, University Hospital of Larissa, Larissa 41110, Greece. ivoutsadakis@yahoo.com Telephone: +30-2410-682028 Fax: +30-2410-682027 Received: February 25, 2009 Revised: May 5, 2009 Accepted: May 12, 2009 Published online: June 7, 2009
Abstract Ampullary carcinoma is the second most common cancer of the peri-ampullary area after pancreatic carcinoma and metastasizes mostly intra-abdominally and to the liver. Extra-abdominal metastases are less frequent. In this report we describe the case of a patient with resected adenocarcinoma of the ampulla of Vater who developed skeletal metastases in the lower extremity and brain metastases. We briefly discuss aspects of this comparatively rare gastrointestinal malignancy.
© 2009 The WJG Press and Baishideng. All rights reserved.
Key words: Adenocarcinoma; Ampulla of Vater; Peri-ampullary; Metastases; Prognosis
Peer reviewer: Kiichi Tamada, MD, Department of Gastroenterology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachigun, Tochigi 329-0498, Japan
Voutsadakis IA, Doumas S, Tsapakidis K, Papagianni M, Papandreou CN. Bone and brain metastases from ampullary adenocarcinoma. World J Gastroenterol 2009; 15(21): 2665-2668 Available from: URL: http://www.wjgnet.com/1007-9327/15/2665.asp DOI: http://dx.doi.org/10.3748/wjg.15.2665
INTRODUCTION The ampulla of Vater includes a common channel derived from the conjunction of the common bile duct and the pancreatic duct, the intra-duodenal parts of these two ducts and the duodenal mucosa surrounding the opening[1]. Peri-ampullary carcinomas arise from the ampulla of Vater, distal bile duct, pancreas or duodenal epithelium and are managed with surgical excision when resectable. Regional and other abdominal lymph nodes and the liver are the primary metastatic sites. Other sites of metastasis are less common but can be encountered especially in long term survivors. We present the case of a patient with ampullary carcinoma and local recurrence developing both biopsy-proven bone metastases in unusual locations and brain metastases.
CASE REPORT A 62-year-old woman presented to the orthopedic clinic complaining of painful localized edema involving the right ankle and shin. Two years earlier, she had undergone surgery for a stage ⅡA (pT3N0M0) low grade ampullary adenocarcinoma. She had developed mesenteric and retroperitoneal lymph node metastases 4 mo postoperatively. At that time the patient had refused chemotherapy since she was asymptomatic.
Diagnostic
work-up of leg symptoms included an X-ray of the right foot and tibia,
which revealed an ill-defined radio-opaque lesion of the right cuneiform
bone and a radiolucent lesion of the tibia (Figure
1). An MRI scan of the right lower extremity disclosed multiple
confluent bone erosions at the diaphysis of the tibia, with significant
extention both proximally and distally. A technetium bone scan showed
increased uptake in the right foot and tibia but no other skeletal
lesions (Figure
2). A follow-up staging CT of the chest, abdomen and pelvis revealed two liver lesions, disseminated bilateral metastatic pulmonary nodules as well as borderline enlarged lymph nodes across the aortic arch and trachea bifurcation. At this time the patient consented to palliative chemotherapy and gemcitabine 1000 mg/m2 iv weekly was administered. Six months later the patient developed changes in mood, and behavior. A brain CT scan demonstrated ring enhancing lesions affecting the right frontal and left temporal lobes as well as the left cerebellar hemisphere. Palliative whole brain radiation followed by palliative targeted therapy with erlotinib 150 mg/d po was administered. The patient died with progressive disease 7 mo later and about 3 years after the diagnosis of her disease.
DISCUSSION Carcinoma of the ampulla of Vater is a rare tumor accounting for approximately 0.2% of all gastrointestinal malignancies with an estimated incidence of less than 6 cases per million people per year. However, it is the second most common peri-ampullary neoplasm following pancreatic carcinoma in incidence. The peak incidence is in the 7th and 8th decades of life. There is a slight male to female preponderance[2]. The adenoma to adenocarcinoma carcinogenesis sequence model seems to be applicable to these tumors, given that the incidence of adenoma surrounding carcinoma of the papilla of Vater ranges from 82% to 91%[3]. Intestinal and pancreaticobiliary types represent the most common histological subtypes, indicating that peri-ampullary carcinomas emanate from the corresponding epithelia covering the distal parts of pancreatic and common bile duct and peri-ampullary duodenum, respectively[2]. A more favorable prognosis of the intestinal sub-type compared with the pancreatico-biliary type has been observed in some series[1,4,5]. Other histologic types less commonly seen in an ampullary location include mucinous, signet-ring cell, neuroendocrine and undifferentiated carcinomas[2,6-9]. Compared to other upper GI tract sites, as well as its periampullary counterparts, ampullary cancer has a favorable prognosis possibly due to the relatively early presentation with jaundice, rendering it resectable in 80%-90% of cases[10,11]. Moreover molecular lesions of ampullary carcinoma are different from other peri-ampullary cancers, a fact that may also contribute to the different prognosis[12]. For example k-ras, which is mutated in 90% of pancreatic cancers, is mutated in only half of the ampullary carcinomas. Overall the 5-year survival rate ranges from 33% to 67.7% in resected cases[10,12-14]. Tumor size and grade, lymph node status and number of positive nodes, perineural infiltration and surgical margins are the most crucial predictors of survival in localized disease[15-18]. Vascular invasion, ulcerative tumor, pancreatic invasion, age and peri-operative blood transfusions are additional prognostic factors seen in some series[18-21]. Nodal involvement is the most robust predictor of survival and forms the basis for recommending adjuvant radiotherapy and chemotherapy to decrease the incidence of locoregional recurrence and distal metastases respectively. Expression of specific proteins by immunohistochemistry has also been linked to prognosis. Expression of transcription factor CDX2 (Caudal-type homeodomain transcription factor), a regulator of normal intestinal and colonic epithelial differentiation, has been linked to improved prognosis compared with ampullary tumors that do not express the transcription factor[22]. In contrast high expression of the transporter protein hENT1 (human Equilibrative nucleoside transporter 1) has been shown to correlate with a shorter survival compared with ampullary carcinomas that displayed low expression of the transporter[23]. Ampullary cancer usually metastasizes to regional nodes, liver, adjacent organs and lungs. In contrast skeletal and brain metastases are common with other primary tumor locations such as lung and breast. We present a patient with an ampullary tumor that developed both bone metastases in unusual locations and brain metastases during the course of her disease. Bone and brain metastases from ampullary carcinoma are not very commonly seen in practice and are rarely reported in the literature. In a series of 135 patients with ampullary cancer who had previously undergone pancreaticoduodenectomy, bone metastases were seen in 5% and brain metastases in less than 4%[13]. In a smaller series of 14 cases of carcinomas of the ampulla of Vater, two had brain metastases but they concerned patients with carcinomas with neuroendocrine differentiation[8], while bone metastases were reported in three cases of another series of 24 patients (13%)[24]. Other isolated cases of bone metastases and unusual metastatic locations, such as the ureter, ovaries, testes, bronchus, umbilicus and distal lymph nodes have also been reported[25-30]. The specific location of bone metastases from ampullary carcinoma are not in general reported and, thus, it is unknown if the common sites seen in several malignancies such as the spine, pelvis and proximal lower extremities are also the most frequent sites of bone metastases in this malignancy. Although no randomized trials have been performed to support adjuvant treatment, local radiation therapy concomitant with 5-fluoropyrimidine-based chemotherapy has been advocated for resected ampullary carcinoma with adverse prognostic features such as size greater than 2 cm, positive lymph nodes, positive surgical margins, poor differentiation and neurovascular invasion[31,32]. In one of these series with 12 patients using protracted infusion of 5-FU concomitantly with radiation treatment, a 2 years survival rate of 89% and a median survival time of 34 mo was reported[32]. In another series a statistically significant improvement in 3 years survival was observed with adjuvant chemoradiotherapy compared with no adjuvant treatment only in patients with high risk characteristics but not in the whole group[31]. In metastatic disease palliative chemotherapy is based on pancreatic cancer type regimens with fluoro-pyrimidines, gemcitabine and platinum derivatives. Resection of solitary liver metastases in an attempt at palliation and prolongation of survival has been done and should be considered in appropriately selected patients[33]. In conclusion, despite their infrequency, bone metastases in the extremities and brain metastases should be included in the differential diagnosis of patients with a history of ampullary carcinoma who present with symptoms referring to such locations in order to expedite the diagnosis and facilitate treatment.
REFERENCES 1 Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11: 223-231 PubMed DOI 2 Fischer HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11: 301-309 PubMed DOI 3 Miyazaki M, Takada T, Miyakawa S, Tsukada K, Nagino M, Kondo S, Furuse J, Saito H, Tsuyuguchi T, Chijiiwa K, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Amano H, Miura F. Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors. J Hepatobiliary Pancreat Surg 2008; 15: 15-24 PubMed DOI 4 Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ, Mathisen O, Clausen OP, Gladhaug IP. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008; 8: 170 PubMed DOI 5 Schirmacher P, Büchler MW. Ampullary adenocarcinoma - differentiation matters. BMC Cancer 2008; 8: 251 PubMed DOI 6 Ramia JM, Mansilla A, Villar J, Muffak K, Garrote D, Ferron JA. Signet-ring-cell carcinoma of the Vater's ampulla. JOP 2004; 5: 495-497 PubMed 7 Purohit RC, Kant K, Bhargava N, Kothari N, Purohit V. Signet ring cell carcinoma of ampulla of Vater in a young adult. Indian J Gastroenterol 2005; 24: 222-223 PubMed 8 Nassar H, Albores-Saavedra J, Klimstra DS. High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol 2005; 29: 588-594 PubMed 9 Sun JH, Chao M, Zhang SZ, Zhang GQ, Li B, Wu JJ. Coexistence of small cell neuroendocrine carcinoma and villous adenoma in the ampulla of Vater. World J Gastroenterol 2008; 14: 4709-4712 PubMed DOI 10 Brown KM, Tompkins AJ, Yong S, Aranha GV, Shoup M. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140: 529-532; discussion 532-533 PubMed DOI 11 Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228: 87-94 PubMed DOI 12 Duffy JP, Hines OJ, Liu JH, Ko CY, Cortina G, Isacoff WH, Nguyen H, Leonardi M, Tompkins RK, Reber HA. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003; 138: 941-948; discussion 948-950 PubMed 13 Hsu HP, Yang TM, Hsieh YH, Shan YS, Lin PW. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007; 14: 50-60 PubMed DOI 14 Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999; 134: 526-532 PubMed DOI 15 Qiao QL, Zhao YG, Ye ML, Yang YM, Zhao JX, Huang YT, Wan YL. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007; 31: 137-143; discussion 144-146 PubMed DOI 16 Sakata J, Shirai Y, Wakai T, Yokoyama N, Sakata E, Akazawa K, Hatakeyama K. Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol 2007; 33: 346-351 PubMed DOI 17 Sakata E, Shirai Y, Yokoyama N, Wakai T, Sakata J, Hatakeyama K. Clinical significance of lymph node micrometastasis in ampullary carcinoma. World J Surg 2006; 30: 985-991 PubMed DOI 18 Moriya T, Kimura W, Hirai I, Mizutani M, Ma J, Kamiga M, Fuse A. Nodal involvement as an indicator of postoperative liver metastasis in carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 2006; 13: 549-555 PubMed DOI 19 Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Furuse J, Saito H, Tsuyuguchi T, Yamamoto M, Kayahara M, Kimura F, Yoshitomi H, Nozawa S, Yoshida M, Wada K, Hirano S, Amano H, Miura F. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg 2008; 15: 41-54 PubMed DOI 20 Chiche L, Alkofer B, Parienti JJ, Rouleau V, Salamé E, Samama G, Segol P. Usefulness of follow-up after pancreatoduodenectomy for carcinoma of the ampulla of Vater. HPB (Oxford) 2007; 9: 140-145 PubMed DOI 21 Balachandran P, Sikora SS, Kapoor S, Krishnani N, Kumar A, Saxena R, Kapoor VK. Long-term survival and recurrence patterns in ampullary cancer. Pancreas 2006; 32: 390-395 PubMed DOI 22 Hansel DE, Maitra A, Lin JW, Goggins M, Argani P, Yeo CJ, Piantadosi S, Leach SD, Biankin AV. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 2005; 23: 1811-1818 PubMed DOI 23 Santini D, Perrone G, Vincenzi B, Lai R, Cass C, Alloni R, Rabitti C, Antinori A, Vecchio F, Morini S, Magistrelli P, Coppola R, Mackey JR, Tonini G. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol 2008; 19: 724-728 PubMed DOI 24 Todoroki T, Koike N, Morishita Y, Kawamoto T, Ohkohchi N, Shoda J, Fukuda Y, Takahashi H. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 2003; 10: 1176-1183 PubMed DOI 25 Stenner J, Arista-Nasr J, Leňero-Llaca E, Keirns C, Gabilondo-Navarro F. Adenocarcinoma of the ampulla of Vater and head of the pancreas metastatic to the ureter: report of 2 cases. J Urol 1996; 156: 1765 PubMed DOI 26 Kim KH, Kim CD, Lee HS, Hyun JH, Kim YS, Kim IS. Bilateral ovarian carcinoma metastatic from the ampulla of Vater: a rare Krukenberg tumor. J Korean Med Sci 1999; 14: 220-222 PubMed 27 Dookeran KA, Lotze MT, Sikora SS, Rao UN. Pancreatic and ampullary carcinomas with intrascrotal metastases. Br J Surg 1997; 84: 198-199 PubMed DOI 28 Akoglu S, Uçan ES, Celik G, Sener G, Sevinç C, Kilinç O, Itil O. Endobronchial metastases from extrathoracic malignancies. Clin Exp Metastasis 2005; 22: 587-591 PubMed 29 Coco C, Manno A, Verbo A, D'Alba P, Pierconti F, De Gaetano AM, Pedretti G, Petito L, Rizzo G, Masi A, Picciocchi A. Metastatic tumors of the umbilicus: report of two cases and review of the literature. Tumori 2005; 91: 206-209 PubMed 30 Moriya T, Kimura W, Hirai I, Mizutani M, Yamamoto T, Toya R, Kamiga M, Fuse A. Twelve years survival with repeated hepatectomy and lung resection for metastasis from carcinoma of the papilla of Vater after pancreaticoduodenectomy. Hepatogastroenterology 2007; 54: 1652-1654 PubMed 31 Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, Rosato EF. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 2000; 47: 945-953 PubMed DOI 32 Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ. Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Arch Surg 2001; 136: 65-69 PubMed DOI 33 Yoshida T, Matsumoto T, Sasaki A, Bandoh T, Kawano K, Kitano S, Gotanda T. Hepatectomy for liver metastasis from ampullary cancer after pancreatoduodenectomy. Hepatogastroenterology 2002; 49: 247-248 PubMed
S- Editor Tian L L- Editor O'Neill M E- Editor Lin YP
| |||
|
|
